Owning theClock
A BENCHMARK OWNED BY THE VENDOR
STOPS BEING EVIDENCE
When terms are not disclosed the reflex is to assume the deal was small and move on, and I have stopped doing that, because undisclosed is a decision somebody made rather than an absence of information. On the twenty ninth of April 2026 Infinite Epigenetics acquired Tally Health in an asset purchase. The asset here was never the supplements, or even the brand. It was the benchmark, and a benchmark owned by the vendor quietly stops functioning as evidence.
Read what actually changed hands
I get bloodwork drawn specifically to check whether the things I take do what they claim, which makes me the customer this deal is about, so I read the announcement twice.
Tally Health was co founded in 2023 by the Harvard geneticist David Sinclair and sells an epigenetic biological age test alongside a supplement line. The buyer also owns TruDiagnostic and states it holds among the largest private datasets of adult DNA methylation. Tally continues as a standalone brand under Melanie Goldey. The obvious description is that a longevity company bought a longevity company. My read is that what moved was a methylation dataset and a competing clock, and the supplements came along attached to them.
A clock is a model, so owning it means defining the year
Biological age is not a measurement the way height is a measurement. It is a model. Somebody decides what counts as a year, which markers matter, and what the reference population looks like. Two clocks can read the same blood and disagree, and neither is lying.
This is where I would push back on how the field talks about itself, because a biological age result is handed to consumers with the confidence of a bathroom scale and is nothing of the kind. If you already hold the largest reference dataset and then buy the most consumer visible rival clock, you have not added a product to a catalogue. You have consolidated the definition, and every longevity intervention hoping to claim it works eventually validates against somebody's clock. There is now one fewer somebody.
Which is precisely the problem with my own bloodwork
Follow the thesis to where it lands on me. If the benchmark is the asset, then the company selling the intervention now owns the instrument grading whether the intervention worked, and the number I am paying for stops being independent evidence and becomes a number with an interest in the answer.
I want to be careful and precise. I have no evidence of manipulation, nothing in the announcement suggests any such intent, and vertical structures like this are ordinary in diagnostics and not improper in themselves. But independence is not a bonus feature of a benchmark. It is the entire reason a benchmark means anything, and it is a strange thing to own both sides of.
My call
The most strategically interesting deal on my list and the one carrying the least public information, which I do not think is unrelated. The test is narrow and checkable. Does Tally's test keep reporting on its own clock, or does it quietly migrate onto TruDiagnostic's? That single answer separates a portfolio addition from a consolidation of the definition, and I know which way I am leaning.
Independence is not a feature of a benchmark. It is the entire reason a benchmark means anything.
Sources
- Infinite Epigenetics announcement of the Tally Health asset purchase, 29 April 2026. Terms not disclosed by either party.
- Tally Health founding, leadership and product scope, and Infinite Epigenetics' ownership of TruDiagnostic, per the announcement.